<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04936490</url>
  </required_header>
  <id_info>
    <org_study_id>1400.059</org_study_id>
    <nct_id>NCT04936490</nct_id>
  </id_info>
  <brief_title>Crocin Supplementation in CSCR</brief_title>
  <official_title>Efficacy and Safety of Crocin Supplementation in Patients With Central Serous Chorioretinopathy (CSCR)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shiraz University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shiraz University of Medical Sciences</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Preclinical and clinical evidence support the protective effect of crocin on different&#xD;
      pathologic pathways involved in central serous chorioretinopathy (CSCR). They involve&#xD;
      inflammation, oxidative stress, mineralocorticoid pathway, and also stress-related injuries.&#xD;
      It also showed that crocin has a protective effect on the retinal pigmented epithelium (RPE)&#xD;
      layer. Based on the mentioned evidence the study designed to evaluate the efficacy and safety&#xD;
      of 2-month crocin supplementation (15 mg/d) in 40 patients with CSCR in a randomized&#xD;
      controlled blinded clinical trial.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2021</start_date>
  <completion_date type="Anticipated">November 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Best-corrected visual acuity (BCVA)</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Foveal thickness (μm)</measure>
    <time_frame>8 weeks</time_frame>
    <description>measured by OCT imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subretinal fluid height (μm)</measure>
    <time_frame>8 weeks</time_frame>
    <description>measured by OCT imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subfoveal choroidal thickness (μm)</measure>
    <time_frame>8 weeks</time_frame>
    <description>measured by OCT imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants need to laser therapy</measure>
    <time_frame>8 weeks</time_frame>
    <description>based on clinical criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total number of reported adverse events</measure>
    <time_frame>8 weeks</time_frame>
    <description>based on patients reported adverse events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Chorioretinopathy, Central Serous</condition>
  <arm_group>
    <arm_group_label>Crocin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Crocin</intervention_name>
    <description>15 mg/d</description>
    <arm_group_label>Crocin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>15 mg/d</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age of 18-60 years old&#xD;
&#xD;
          -  The diagnosis of CSCR based on clinical and imagining evaluation&#xD;
&#xD;
          -  informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Chronic CSCR&#xD;
&#xD;
          -  Laser treatment (6 months prior to enrollment)&#xD;
&#xD;
          -  IVB treatment (3 months prior to enrollment)&#xD;
&#xD;
          -  Other retinal diseases&#xD;
&#xD;
          -  History of eye diseases&#xD;
&#xD;
          -  Diabetes Mellitus&#xD;
&#xD;
          -  Renal or hepatic diseases&#xD;
&#xD;
          -  Allergy to saffron or crocin&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
&#xD;
          -  Beta-blocker, diuretic, or corticosteroid (1 week prior to enrollment) Bleeding&#xD;
             tendency or any coagulation disorder&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Shiraz University of Medical Sciences</name>
      <address>
        <city>Shiraz</city>
        <state>Fars</state>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mojtaba Heydari, M.D.</last_name>
      <phone>+989172051798</phone>
      <email>mheydari@sums.ac.ir</email>
    </contact>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 2, 2021</study_first_submitted>
  <study_first_submitted_qc>June 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 23, 2021</study_first_posted>
  <last_update_submitted>October 27, 2021</last_update_submitted>
  <last_update_submitted_qc>October 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shiraz University of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Mojtaba Heydari</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Central Serous Chorioretinopathy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

